| Drug / Therapy | A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE) |
| Indication | — |
| Decision Type | Phase 2 |
| Trial Phase | Phase 2 |
| ClinicalTrials.gov | NCT07409181 |
West Pharmaceutical Services, Inc. (WST) operates in the Biotech / Pharma sector. The current BTS Score is 73 (Grade: B).
Biotech companies frequently raise capital through secondary offerings, ATM programs, and convertible notes. Before or after major FDA decisions, dilution events are common. Understanding a company's dilution history is critical for managing risk around catalyst dates.
The Phase 2 date for A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE) by West Pharmaceutical Services, Inc. (WST) is scheduled for February 4, 2029. This is the target date for the FDA to make a decision on this application.
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE) is being developed by West Pharmaceutical Services, Inc. for the treatment of its target indication. It is currently in Phase 2 clinical trials.
If A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE) receives FDA approval, West Pharmaceutical Services, Inc. (WST) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Phase 2 date closely.
Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for WST on DilutionWatch at dilutionwatch.com/stock/WST.html.
You can view the full BiotechSigns company profile for West Pharmaceutical Services, Inc. (WST) at biotechsign.com/app/company/WST, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.
This page is for informational purposes only and does not constitute investment advice. FDA decision dates are subject to change. Clinical trial outcomes are inherently uncertain. Biotech stocks are highly volatile — past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. BiotechSigns is not a registered investment advisor.